Lifeboat Foundation

Female kidneys are known to be more resilient to disease and injury, but males need not despair. A new USC Stem Cell-led study published in Developmental Cell describes not only how sex hormones drive differences in male and female mouse kidneys, but also how lowering testosterone can “feminize” this organ and improve its resilience.

“By exploring how differences emerge in male and female kidneys during development, we can better understand how to address sex-related health disparities for patients with kidney diseases,” said Professor Andy McMahon, the study’s corresponding author, and the director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the Keck School of Medicine of USC.

First authors Lingyun “Ivy” Xiong and Jing Liu from the McMahon Lab and their collaborators identified more than 1,000 genes with different levels of activity in male and female mouse kidneys, in a study supported by the National Institutes of Health. The differences were most evident in the section of the kidney’s filtering unit known as the proximal tubule, responsible for reabsorbing most of the nutrients such as glucose and amino acids back into the blood stream.

An essential protein that acts as a gatekeeper for calcium entering cells promotes the growth of oral cancer and generates pain, according to a new study published in Science Signaling led by researchers at New York University College of Dentistry.

Targeting this protein—the ORAI1 calcium channel —could provide a new approach to treating oral cancer, which causes persistent pain that worsens as it progresses.

“Our results show that the ORAI1 channel fuels the growth of oral cancer tumors and produces an abundance of molecules that, once secreted, interact with neurons resulting in an increased sensitivity to pain,” said Ga-Yeon Son, a postdoctoral fellow in the Department of Molecular Pathobiology at NYU College of Dentistry and the study’s first author.

The current crop of AI robots has made giant leaps when it comes to tiny activities.

There are robots performing colonoscopies, conducting microsurgeries on blood vessels and nerve cells, designing circuit boards, constructing delicate timepieces and conducting fine touch-up operations on fading, aging classical paintings by the masters.

Continue reading “Targeted stiffening yields more efficient soft robot arms” »

As scientists get better at interpreting the language of the brain, they get closer to not just treating disease, but also enhancing our senses and our intellects. Should they go there?

Other questions to the experts in this canvassing invited their views on the hopeful things that will occur in the next decade and for examples of specific applications that might emerge. What will human-technology co-evolution look like by 2030? Participants in this canvassing expect the rate of change to fall in a range anywhere from incremental to extremely impactful. Generally, they expect AI to continue to be targeted toward efficiencies in workplaces and other activities, and they say it is likely to be embedded in most human endeavors.

The greatest share of participants in this canvassing said automated systems driven by artificial intelligence are already improving many dimensions of their work, play and home lives and they expect this to continue over the next decade. While they worry over the accompanying negatives of human-AI advances, they hope for broad changes for the better as networked, intelligent systems are revolutionizing everything, from the most pressing professional work to hundreds of the little “everyday” aspects of existence.

One respondent’s answer covered many of the improvements experts expect as machines sit alongside humans as their assistants and enhancers. An associate professor at a major university in Israel wrote, “In the coming 12 years AI will enable all sorts of professions to do their work more efficiently, especially those involving ‘saving life’: individualized medicine, policing, even warfare (where attacks will focus on disabling infrastructure and less in killing enemy combatants and civilians). In other professions, AI will enable greater individualization, e.g., education based on the needs and intellectual abilities of each pupil/student. Of course, there will be some downsides: greater unemployment in certain ‘rote’ jobs (e.g., transportation drivers, food service, robots and automation, etc.).”

Graphene-based two-dimensional materials have recently emerged as a focus of scientific exploration due to their exceptional structural, mechanical, electrical, optical, and thermal properties. Among them, nanosheets based on graphene-oxide (GO), an oxidized derivative of graphene, with ultrathin and extra wide dimensions and oxygen-rich surfaces are quite promising.

Functional groups containing oxygen, such as carboxy and acidic hydroxy groups, generate dense negative charges, making GO nanosheets colloidally stable in water. As a result, they are valuable building blocks for next-generation functional soft materials.

In particular, thermoresponsive GO nanosheets have garnered much attention for their wide-ranging applications, from smart membranes and surfaces and recyclable systems to hydrogel actuators and biomedical platforms. However, the prevailing synthetic strategies for generating thermoresponsive behaviors entail modifying GO nanosheet surfaces with thermoresponsive polymers such as poly (N-isopropylacrylamide). This process is complex and has potential limitations in subsequent functionalization efforts.

A comprehensive review in the journal Cell outlines a unified framework for classifying and validating aging biomarkers, aiming to streamline their integration into clinical research and practice. The study categorizes biomarkers into types like molecular, functional, and clinical, and sets criteria for their feasibility, validity, and applicability, all with the goal of better understanding and intervening in the aging process.

A groundbreaking medical procedure for those with kidney stones will soon be offered at the University of Washington after more than two decades of research.

A new blood-based diagnostic test could be a major advancement for the treatment of Parkinson’s, a disease that afflicts 10 million people worldwide and is the second-most common neurodegenerative disease after Alzheimer’s.

Building on the knowledge that mitochondrial dysfunction plays a prominent role in the pathogenesis of Parkinson’s a team of researchers, led by neuroscientists at Duke Health, have developed an assay that enables the accurate, real-time quantification of mitochondrial DNA damage in a scalable platform [1]. The results of the study, which received support in part from The Michael J Fox Foundation for Parkinson’s Research, have been published in the journal Science Translational Medicine.

“Currently, Parkinson’s disease is diagnosed largely based on clinical symptoms after significant neurological damage has already occurred,” said senior author Laurie Sanders, PhD, an associate professor in Duke School of Medicine’s departments of Neurology and Pathology and member of the Duke Center for Neurodegeneration and Neurotherapeutics.